This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free Online Activities

The Neurobiology of Cognition in Schizophrenia

Carol A. Tamminga

Published: September 15, 2006

Article Abstract

Cognitive dysfunction in schizophrenia differs from cognitive dysfunction inneurodegenerative illnesses because it is associated with neuronal dysfunctionand not neurodegeneration. Pharmacologically, potential targets for developingtreatments may differ from cognition in dementing disorders. Several putativemolecular targets for treating cognition in schizophrenia show promise, such astreatments that act on the D1 receptor of the dopamine system; the5HT1A, 5HT2A,and 5HT6, receptors of theserotonin system; and ampakines, Glycine/D-cycloserine, D-serine, and mGluR 2/3agonists of the glutamatergic system. Other receptors associated withimprovement in cognition include nicotinic and muscarinic receptors, and theαlpha2subunit receptor of the brain GABA system.  Domain treatment ofschizophrenia is a new method of treating schizophrenia that involves treating asingle domain of dysfunction at a time.

See the entire activity.‘ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: Schizophrenia and Schizoaffective Disorders


Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...